Firstly, a phase II trial of rucaparib for locally advanced/metastatic PC cases harboring BRCA1, BRCA2 or PALB2 mutation is in progress in the Abramson Cancer Center of the University of Pennsylvania, where the clinical efficacy of rucaparib maintenance therapy is being assessed following a platinum-based induction regimen of at least 16 weeks (NCT03140670). The gene discussed is BRCA2; the disease is pachyonychia congenita.